PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ijmedpaedHomeCurrent issueInstructionsSubmit article
 
Indian J Med Paediatr Oncol. 2010 Oct-Dec; 31(4): 132–136.
PMCID: PMC3089921
Targeting mTOR pathway: A new concept in cancer therapy
S. H. Advani
Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India
Address for correspondence: Dr. S. H. Advani, Jaslok Hospital and Research Centre, 15, Dr. Deshmukh Marg, Pedder Road, Mumbai- 400 026, Maharashtra, India. E-mail: shadvani2000/at/yahoo.com
This article highlights the current knowledge of mTOR biology and provides new insights into the role of mTOR in different cancers. An active mTOR coordinates a response in cell growth directly through its effects on cell cycle regulators and indirectly by sustaining nutrient supply into the cell through the production of nutrient transporters and also through the promotion of angiogenesis. A primary way that mTOR exerts its regulatory effects on cell proliferation is by controlling the production of cyclin D1. mTOR increases the translation of hypoxia-inducible factor 1 (HIF-1)/HIF-2. The HIF transcription factors drive the expression of hypoxic stress response genes, including angiogenic growth factors such as vascular endothelial growth factor (VEGF), platelet-derived growth factor β (PDGF-β), and transforming growth factor a (TGF-α). mTOR also increases the surface expression of nutrient transporters proteins. An increase in these proteins results in greater uptake of amino acids and other nutrients by the cell leading to adequate nutrient support to abnormal cell growth and survival. There is also emerging evidence that mTOR activation may play a role in promoting cell survival through the activation of antiapoptotic proteins that contribute to tumor progression. Given that the mTOR pathway is deregulated in a number of cancers, it is anticipated that mTOR inhibitors will have broad therapeutic application across many tumor types. Until now, no treatment demonstrated Phase III evidence after disease progression on an initial VEGF-targeted therapy in advanced renal cell carcinoma. Everolimus is the first and only therapy with Phase III evidence after failure of VEGF-targeted therapy. Everolimus is a once-daily, oral inhibitor of mTOR (mammalian target of rapamycin) indicated for the treatment of advanced renal cell carcinoma in patients, whose disease has progressed on or after treatment with VEGF-targeted therapy.
Keywords: Angiogenesis, bioenergetics, everolimus
The mammalian target of rapamycin (mTOR) pathway is a crucial regulator of cell growth and proliferation and research into this area has revealed that mTOR dysregulation has a key role to play in various cancers. mTOR appears to play a central role in signaling caused by nutrients and mitogens such as growth factors to regulate translation. The understanding of the science behind mTOR’s role as a regulator of many cell processes and its potential as a therapeutic target has opened up treatment possibilities in several types of cancer. This article highlights the current knowledge of mTOR biology and provides new insights into the role of mTOR in different cancers.
mTOR is a 290 kDa serine–threonine kinase that regulates both cell growth and cell cycle progression through its ability to integrate signals from nutrient and growth factor stimuli. mTOR, a member of the phosphatidylinositol 3-kinase (PI3K)-kinase-related kinase (PIKK) superfamily, is composed of 2549 amino acids that are grouped into highly conserved domains. The mTOR is an intracellular kinase that controls the production of proteins through effects on the machinery of mRNA translation. These proteins include important components of several processes critical to cell metabolism, cell growth, cell division, and responses to cellular stresses such as hypoxia or DNA damage.[1,2]
mTOR senses the growth conditions within the cellular environment and helps the cells respond to changes in this environment. An active mTOR coordinates a response in cell growth directly through its effects on cell cycle regulators and indirectly by sustaining nutrient supply into the cell through the production of nutrient transporters and into the cell’s environment through the promotion of angiogenesis. The activation of mTOR signifies a decision point that takes into account the availability of the basic materials required for cell growth (e.g., amino acids, glucose, energy) and the growth-regulating signals from other cells and tissues (e.g., hormones, growth factors) while monitoring conditions of cellular stress (e.g., hypoxia, DNA damage, heat shock, external pH, osmotic stress, oxidative stress). In this manner, the cell is protected from signals outside the cell to grow and proliferate originating when the supply of nutrients and energy inside the cell are not sufficient to support the effort.[3]
Upstream in the growth-promoting pathways are critical molecules that converge on mTOR, which are often deregulated in some manner in cancer. Several mutations found in cancer produce inappropriate signals that activate the mTOR switch, driving the growth and proliferation of the cancer cell.
mTOR senses the availability of nutrients [e.g., adenosine triphosphate (ATP), glucose, amino acids, cholesterol, and iron] and consolidates this information with growth factor signaling through the PI3K/Akt/tuberous sclerosis complex (TSC) pathway.[4] An activated mTOR modulates the rate of protein synthesis for select mRNAs by activating the translational proteins S6 kinase (S6K) and 4E-binding protein 1 (4E-BP1).[1] mTOR activation increases downstream effectors that stimulate cell growth and angiogenesis and regulate cellular metabolism.
A primary way that mTOR exerts its regulatory effects on cell proliferation is by controlling the production of cyclin D1. Cyclins are proteins that regulate the activity of enzymes called cyclin-dependent kinases (CDKs) through the critical G1–S restriction point of the cell cycle, which in turn regulate the passage of cells. Recently, cyclin D1 has been shown to play a role in gene transcription, cell metabolism, and cell migration.
Cyclin D1 overexpression had been associated with a number of cancers including breast cancer, colon cancer, prostate cancer, lymphoma, and melanoma.[5,6]
Mutations in tumor sclerosis complex (TSC1 or TSC2) can also lead to overactivation of mTOR. This overactivation causes unregulated cell proliferation and multisystem tumors in patients with TSC. Increased mTOR activation, as evidenced by hyperphosphorylation of downstream signaling proteins, has been observed in TSC related lesions.[7,8]
mTOR plays a key role in angiogenesis, i.e., the formation of new blood vessels to provide oxygen and nutrients to growing and dividing cells. mTOR increases the translation of hypoxia-inducible factor 1 (HIF-1)/hypoxia-inducible factor 2 (HIF- 2).[9] The HIF transcription factors drive the expression of hypoxic stress response genes, including angiogenic growth factors such as vascular endothelial growth factor (VEGF), platelet-derived growth factor β (PDGF-β), and transforming growth factor-α (TGF-α).[10]
Increased levels of HIF-1α and HIF-1β have been shown to correlate with increased mortality in a number of tumor types, including cervical cancer, breast cancer, non-small-cell lung cancer, ovarian cancer, head and neck cancer, and gastrointestinal stromal tumors.[11] In addition, loss of the von Hippel-Lindau (VHL) protein, which also results in increased levels of HIF-1α, is a primary cause of many cases of renal cell carcinoma (RCC), and has been implicated in pancreatic cancer and neuroendocrine tumors (NETs) as well.[12]
Cells have a complex sensing system designed to ensure that they do not undergo periods of growth unless adequate levels of nutrients are available to produce the energy necessary to support that growth. The rapidly expanding field of study dedicated to understanding how living systems obtain and utilize energy is known as bioenergetics.
Bioenergetic research has shown that mTOR plays a key role in regulating cell metabolism.[4,13] mTOR increases the surface expression of nutrient transporter proteins. An increase in these proteins results in greater uptake of amino acids and other nutrients by the cell, leading to adequate nutrient support to abnormal cell growth and survival.[13]
Additionally, abnormally activated mTOR may give cancer cells a competitive growth advantage by increasing production of the core enzymes necessary for glycolysis, which enables cancer cells to survive and grow even under hypoxic conditions.[14]
There are several lines of evidence that mTOR activity plays a role in cell survival. Majority of this research has revealed that mTOR inhibition increases sensitivity to cell death pathways; however, there is also emerging evidence that mTOR activation may play a role in promoting cell survival through the activation of antiapoptotic proteins that contribute to tumor progression.[15]
A recent study has shown that mTOR activation of pS6K increases protein levels of survivin, an inhibitor of apoptosis protein (IAP). Survivin blocks extrinisic and intrinsic apoptotic pathways, and survivin expression has been observed in a wide number of tumor types and associated with poor prognosis in cancer [Figure 1].[16]
Figure 1
Figure 1
mTOR activation supports cancer cell survival
Thus, overactivation of mTOR due to dysregulation of upstream pathways, leading to abnormal activities in cell progression, angiogenesis, cell metabolism and apoptosis has been implicated in various cancer types.
RENAL CELL CARCINOMA
mTOR controls production of HIF-1α, an important protein in RCC, where its unregulated activity is causally related to disease pathogenesis.[17] mTOR regulates the production of several angiogenic growth factors in RCC. mTOR may control the ability of neovascular cells to respond to growth factors.[13,18] mTOR controls cell growth and cell division in RCC and in cells of the tumor microvasculature, and is often dysregulated in renal cancer by signaling defects upstream of mTOR in the PI3K/Akt/mTOR pathway.[19] mTOR regulates nutrient uptake and cell metabolism and contributes to the characteristic metabolic changes in RCC.[1]
Several important molecular changes in NETs involve the mTOR pathway. Increased growth factor signaling, namely, epidermal growth factor (EGF) and insulin-like growth factor (IGF) signaling upstream of mTOR, has been observed frequently in NETs.[20] Also, insulin secretion is believed to be involved in the autocrine activation of mTOR in pancreatic beta cell tumors.[21] mTOR is activated by many gene mutations associated with NETs (germline deletion of the VHL gene).[12] mTOR directs the supply of nutrients to cancer cells by regulating angiogenesis. NETs are highly vascular.[22] VEGF expression has been observed in 80–86% of gastrointestinal carcinoid and pancreatic islet cell tumors.[23]
mTOR is activated in 60–80% of gastric adenocarcinomas[24,25] and is expressed in early-stage and advanced-stage disease, in both diffuse and intestinal subtypes, and in tumor cells that invade lymphatic channels. The mTOR pathway is activated by multiple growth factor receptors, namely, epidermal growth factor receptor (EGFR), Human Epidermal growth factor Receptor 2 (HER2), insulin-like growth factor type 1 receptor (IGF-1R), that are overexpressed in many gastric tumors.[26,27] mTOR regulates production of angiogenic factors (VEGF/VEGFR) that promote new vessel formation and predict poor outcome in patients with gastric cancer.[28] mTOR regulates nutrient uptake and cell metabolism and contributes to the characteristic metabolic changes in cancer. HIF-1α is expressed in most gastric cancers, and HIF-1α expression at the invading tumor edge is associated with advanced-stage disease, lymph node metastases, and poor survival.[29,30]
BREAST CANCER
mTOR signaling is critical in the pathogenesis of breast cancer. mTOR signaling may be related to estrogen receptor (ER) activation and adaptive estrogen hypersensitivity.[31] mTOR pathway signaling is increased in HER2+ tumor cells resistant to endocrine therapy.[32] mTOR activation predicts a worse clinical outcome for patients treated with endocrine therapy.[33] mTOR controls the supply of nutrients to cancer cells by regulating nutrient uptake, cell metabolism, and angiogenesis.
mTOR-dependent signaling is active in 25–45% of hepatocellular carcinoma (HCC).[34] Activation correlates with shorter overall survival; mTOR activation is an independent predictor of recurrence after surgery.[35] mTOR regulates production of angiogenic factors. High VEGF levels have been associated with tumor cell proliferation, poor encapsulation of the tumor nodules, venous invasion, higher grade, and a poor prognosis following resection.[36] mTOR activation through PI3K/Akt pathway is associated with increased expression of growth factors such as EGF, TGF-α, IGF, and hepatocyte growth factor (HGF) that promote HCC cell proliferation and survival.[37,38]
LYMPHOMA
Approximately 85% of Non-Hodgkin lymphoma (NHL) s arise from cells of B-cell lineage.[39] mTOR signaling is activated in Hodgkin lymphoma cell lines and primary tumors.[40] Cyclin D1 overexpression is a characteristic feature of mantle cell lymphomas.[41] PI3K and Akt overexpression is frequently observed in several B-cell lymphomas.[42]
Because the number of potential defects that can cause inappropriate activation of mTOR is large and one or the other is common to most cancer cells, blocking their effect at the point of convergence is a rational approach. The mTOR protein itself is seldom altered, suggesting that mTOR is a stable target for influencing several important pathways in cancer.[43] Furthermore, identifying these molecular defects in a tumor may provide the biomarkers that determine whether the cancer will be sensitive to mTOR inhibition and help select the most appropriate treatment strategy.
Thus far, clinical studies have supported preclinical findings regarding the importance of mTOR in cancer and validate mTOR inhibition as an effective cancer therapy. Given that the mTOR pathway is deregulated in a number of cancers, it is anticipated that mTOR inhibitors will have broad therapeutic application across many tumor types. It is possible that only a subset of cancer patients will have tumors sensitive to mTOR inhibitors as a monotherapy. Based on preclinical findings, mTOR inhibitors may be more efficacious when used in rational combination with other cancer regimens with activities supplemental to and/or influenced by mTOR activity, such as DNA-damaging and hormonal agents, oncogene inhibitors, and other targeted therapies. Thus, mTOR inhibitors may play an important role in the management of cancer. mTOR inhibition has been proven to result in reduced tumor cell growth and proliferation, decreased tumor angiogenesis and inhibition of cell metabolism.
Treatment of advanced RCC has evolved rapidly in the last few years. The emergence of multiple new treatments has led to frequent use of sequential VEGF tyrosine kinase inhibitor (TKI) therapy. Until now, no treatment demonstrated Phase III evidence after disease progression on an initial VEGF-targeted therapy. Everolimus is the first and only therapy with Phase III evidence after failure of VEGF-targeted therapy. Everolimus is a once-daily oral inhibitor of mTOR indicated for the treatment of advanced RCC in patients whose disease has progressed on or after treatment with VEGF-targeted therapy.
CONCLUSION
mTOR inhibitors are being investigated in clinical trials in several hematologic, gastrointestinal, genitourinary, and neurologic cancers, NETs, and sarcomas, as well as in breast and lung cancers. It is hoped that with this added knowledge, the potential beneficial effects of inhibiting mTOR signaling in cancer patients will be fully recognized and realized in clinical practice.
Footnotes
Source of Support: Nil
Conflict of Interest: None declared.
1. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926–45. [PubMed]
2. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res. 2007;13:3109–14. [PubMed]
3. Dancey JE. Therapeutic targets: mTOR and related pathways. Cancer Biol Ther. 2006;5:1065–73. [PubMed]
4. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–84. [PubMed]
5. Nelsen CJ, Rickheim DG, Tucker MM, Hansen LK, Albrecht JH. Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes. J Biol Chem. 2003;278:3656–63. [PubMed]
6. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: Normal and abnormal functions. Endocrinology. 2004;145:5439–47. [PubMed]
7. El-Hashemite N, Zhang H, Henske EP, Kwiatkowski DJ. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet. 2003;361:1348–9. [PubMed]
8. Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM) J Biol Chem. 2002;277:30958–67. [PubMed]
9. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, et al. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006;66:5549–54. [PubMed]
10. Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res. 2006;12:7215–20. [PubMed]
11. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721–32. [PubMed]
12. Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d’Etude de la Maladie de von Hippel-Lindau. Gastroenterology. 2000;119:1087–95. [PubMed]
13. Pantuck AJ, Thomas G, Belldegrun AS, Figlin RA. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications. Semin Oncol. 2006;33:607–13. [PubMed]
14. Shaw RJ. Glucose metabolism and cancer. Curr Opin Cell Biol. 2006;18:598–608. [PubMed]
15. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424–30. [PubMed]
16. Vaira V, Lee CW, Goel HL, Bosari S, Languino LR, Altieri DC. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene. 2007;26:2678–84. [PubMed]
17. Samlowski WE, Vogelzang NJ. Emerging drugs for the treatment of metastatic renal cancer. Expert Opin Emerg Drugs. 2007;12:605–18. [PubMed]
18. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J. 2002;16:771–80. [PubMed]
19. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006;12:122–7. [PubMed]
20. Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol. 2005;18:1329–35. [PubMed]
21. McDaniel ML, Marshall CA, Pappan KL, Kwon G. Metabolic and autocrine regulation of the mammalian target of rapamycin by pancreatic beta-cells. Diabetes. 2002;51:2877–85. [PubMed]
22. Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer. 2007;109:1478–86. [PubMed]
23. Terris B, Scoazec JY, Rubbia L, Bregeaud L, Pepper MS, Ruszniewski P, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology. 1998;32:133–8. [PubMed]
24. Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer. 2007;120:1803–10. [PubMed]
25. Feng W, Brown RE, Trung CD, Li W, Wang L, Khoury T, et al. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. Ann Clin Lab Sci. 2008;38:195–209. [PubMed]
26. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: Prognostic significance of protein overexpression and high gene copy number. Histopathology. 2008;52:738–46. [PubMed]
27. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 2008;15:69–79. [PubMed]
28. Fondevila C, Metges JP, Fuster J, Grau JJ, Palacín A, Castells A, et al. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer. 2004;90:206–15. [PMC free article] [PubMed]
29. Griffiths EA, Pritchard SA, Valentine HR, Whitchelo N, Bishop PW, Ebert MP, et al. Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer. 2007;96:95–103. [PMC free article] [PubMed]
30. Rohwer N, Lobitz S, Daskalow K, Jöns T, Vieth M, Schlag PM, et al. HIF-1alpha determines the metastatic potential of gastric cancer cells. Br J Cancer. 2009;100:772–81. [PMC free article] [PubMed]
31. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res. 2004;10:8059–67. [PubMed]
32. Pérez-Tenorio G, Stål O. Southeast Sweden Breast Cancer Group. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer. 2002;86:540–5. [PMC free article] [PubMed]
33. Tokunaga E, Kataoka A, Kimura Y, Oki E, Mashino K, Nishida K, et al. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer. 2006;42:629–35. [PubMed]
34. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res. 2004;10:8421–5. [PubMed]
35. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135:1972–83. [PMC free article] [PubMed]
36. Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT. Biology of hepatocellular carcinoma. Ann Surg Oncol. 2008;15:962–71. [PubMed]
37. Greten TF, Korangy F, Manns MP, Malek NP. Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer. 2009;100:19–23. [PMC free article] [PubMed]
38. Höpfner M, Schuppan D, Scherübl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol. 2008;14:1–14. [PMC free article] [PubMed]
39. American Cancer Society. Detailed guide: lymphoma, non-Hodgkin type. Available from: http://www.cancer.org [last accessed on 2010 Oct 25]
40. Drakos E, Rassidakis GZ, Medeiros LJ. Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas. Expert Rev Mol Med. 2008;10:e4. [PubMed]
41. Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs. 2006;17:487–94. [PubMed]
42. Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 2001;61:2194–9. [PubMed]
43. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: Mechanism of action and cellular resistance. Cancer Biol Ther. 2003;2:222–32. [PubMed]
Articles from Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology are provided here courtesy of
Medknow Publications